Insmed Sees Unusually High Options Volume (NASDAQ:INSM)

Insmed Incorporated (NASDAQ:INSM) was the recipient of unusually large options trading on Monday. Stock traders bought 1,584 put options on the stock. This is an increase of 1,550% compared to the typical volume of 96 put options.

In related news, CAO John Goll sold 25,000 shares of the company’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $20.80, for a total transaction of $520,000.00. Insiders own 4.95% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the business. Aperio Group LLC increased its holdings in shares of Insmed by 21.0% in the second quarter. Aperio Group LLC now owns 11,402 shares of the biopharmaceutical company’s stock valued at $292,000 after purchasing an additional 1,977 shares during the period. DekaBank Deutsche Girozentrale raised its position in Insmed by 54.6% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 51,800 shares of the biopharmaceutical company’s stock worth $1,311,000 after buying an additional 18,300 shares during the last quarter. C WorldWide Group Holding A S raised its position in Insmed by 247.5% during the 2nd quarter. C WorldWide Group Holding A S now owns 393,110 shares of the biopharmaceutical company’s stock worth $10,064,000 after buying an additional 280,000 shares during the last quarter. Swiss National Bank lifted its stake in Insmed by 9.7% during the 2nd quarter. Swiss National Bank now owns 154,100 shares of the biopharmaceutical company’s stock valued at $3,945,000 after acquiring an additional 13,600 shares during the period. Finally, Hillsdale Investment Management Inc. acquired a new stake in Insmed during the 2nd quarter valued at approximately $740,000.

NASDAQ INSM opened at $23.08 on Tuesday. Insmed has a 12-month low of $11.31 and a 12-month high of $33.13. The company has a fifty day simple moving average of $19.54 and a two-hundred day simple moving average of $20.72. The company has a current ratio of 6.97, a quick ratio of 6.70 and a debt-to-equity ratio of 1.19. The stock has a market cap of $2.06 billion, a P/E ratio of -5.53 and a beta of 3.04.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Wednesday, October 30th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.01). Insmed had a negative net margin of 291.19% and a negative return on equity of 114.68%. The company had revenue of $38.89 million for the quarter, compared to analysts’ expectations of $35.89 million. During the same period last year, the firm earned ($1.14) earnings per share. As a group, sell-side analysts forecast that Insmed will post -2.91 earnings per share for the current year.

A number of equities analysts have commented on the stock. ValuEngine upgraded shares of Insmed from a “hold” rating to a “buy” rating in a report on Monday, November 25th. HC Wainwright restated a “buy” rating on shares of Insmed in a report on Thursday, October 31st. Morgan Stanley set a $37.00 price objective on shares of Insmed and gave the stock a “buy” rating in a research report on Friday, November 1st. Goldman Sachs Group initiated coverage on shares of Insmed in a research note on Tuesday, September 3rd. They set a “buy” rating and a $30.00 price objective for the company. Finally, Credit Suisse Group reaffirmed a “buy” rating and issued a $40.00 price target on shares of Insmed in a report on Tuesday, September 10th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $35.88.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Featured Article: Trading signals using Bollinger bands

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.